Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02596997

Expanded Access Status : No longer available

First Posted : November 4, 2015

Last Update Posted : March 14, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Chimerix

Tracking Information
First Submitted Date	November 3, 2015
First Posted Date	November 4, 2015
Last Update Posted Date	March 14, 2022

Descriptive Information
Brief Title	Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Brief Summary	Provide patients with serious AdV infection or disease access to treatment with BCV.
Detailed Description	Not Provided
Study Type	Expanded Access
Intervention	Drug: Brincidofovir Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week Other Name: BCV CMX001
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Expanded Access Status	No longer available
Contacts	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries	United States
Removed Location Countries

Administrative Information
NCT Number	NCT02596997
Current Responsible Party	Chimerix
Original Responsible Party	Same as current
Current Study Sponsor	Chimerix
Original Study Sponsor	Same as current
Collaborators	Not Provided
Investigators	Not Provided
PRS Account	Chimerix
Verification Date	February 2020

To Top